Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...
MarketBeat on MSN3h
Vertex's Pain Drug: Big Pharma's Next Major Success?Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback